ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.065,44
-1,55%
S&P 500
5.702,55
-0,19%
US Dollar vs BRL
5,5151
0,00%
Bitcoin
62.952,45
-0,67%
Brent Oil
74,135
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cadrenal Therapeutics Inc (CVKD)

  7. Cadrenal Therapeutics Inc (CVKD) Notícias

CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CVKD
DataHoraFonteTítuloCódigoCompanhia
05/09/202417:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
22/08/202410:00PR Newswire (US)Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
20/08/202410:00PR Newswire (US)Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
14/08/202410:00PR Newswire (US)Cadrenal Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CVKDCadrenal Therapeutics Inc
07/08/202417:05PR Newswire (US)Cadrenal Therapeutics Provides Second Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
07/08/202417:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
06/08/202410:00PR Newswire (US)Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADsNASDAQ:CVKDCadrenal Therapeutics Inc
12/06/202417:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202418:27Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202418:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
03/06/202410:00PR Newswire (US)Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
29/05/202418:27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
23/05/202410:00PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202410:00PR Newswire (US)Cadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
11/04/202417:30PR Newswire (US)Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/04/202410:00PR Newswire (US)Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsNASDAQ:CVKDCadrenal Therapeutics Inc
11/03/202410:00PR Newswire (US)Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
26/02/202411:00PR Newswire (US)Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
15/02/202410:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CVKDCadrenal Therapeutics Inc
08/02/202411:00PR Newswire (US)Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialNASDAQ:CVKDCadrenal Therapeutics Inc
31/01/202411:00PR Newswire (US)Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsNASDAQ:CVKDCadrenal Therapeutics Inc
24/01/202411:00PR Newswire (US)Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
04/01/202411:00PR Newswire (US)Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
19/12/202311:00PR Newswire (US)Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetNASDAQ:CVKDCadrenal Therapeutics Inc
12/12/202311:00PR Newswire (US)Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationNASDAQ:CVKDCadrenal Therapeutics Inc
30/11/202318:15PR Newswire (US)Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:CVKDCadrenal Therapeutics Inc
09/11/202311:00PR Newswire (US)Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
09/10/202317:15PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
05/09/202309:00PR Newswire (US)Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressNASDAQ:CVKDCadrenal Therapeutics Inc
30/08/202309:00PR Newswire (US)Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)NASDAQ:CVKDCadrenal Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CVKD

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
COGN3
COGNA ON
BOV
TTEN3
3TENTOS ON NM ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados